For the year ended March 31, the Manchester, UK-based provider of noninvasive prenatal testing reported more than £3.1 million ($4 million) in revenue.
LifeCodexx's PrenaTest will be available to women in Malaysia, Singapore, Thailand, Brunei, Vietnam, the United Arab Emirates, and elsewhere in the Middle East.
A new study shows that combining size-based and count-based analysis helps determine whether a copy number aberration originates in the mother, fetus, or both.
The company plans to launch the new qNIPT test, which uses methylation-specific quantitative PCR to detect fetal epigenetic biomarkers, in the near future.
Based on data from more than 6,000 clinical cases, the investigators from Switzerland advocated for an expansion of NIPT to cover additional alterations and associated phenotypes.
